Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 8/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL946943 | 0.91 | BTK (0.50) | KDM1AMAOBBTKDRD2DRD3 | |
| SCHEMBL946942 | 0.91 | BTK (0.50) | KDM1AMAOBBTKDRD2DRD3 | |
| SCHEMBL1067922 | 0.91 | BTK (0.50) | KDM1AMAOBBTKDRD2DRD3 | |
| SCHEMBL28225775 | 0.85 | BTK (0.55) | KDM1AMAOBBTKDRD2DRD3 | |
| SCHEMBL22488855 | 0.85 | DRD2 (0.49) | KDM1AMAOBBTKDRD2DRD3 | |
| SCHEMBL21482088 | 0.85 | DRD2 (0.49) | KDM1AMAOBBTKDRD2DRD3 | |
| SCHEMBL19445904 | 0.85 | DRD2 (0.49) | KDM1AMAOBBTKDRD2DRD3 | |
| SCHEMBL22489272 | 0.84 | DRD2 (0.48) | KDM1AMAOBBTKDRD2DRD3 | |
| SCHEMBL30199256 | 0.84 | DRD2 (0.48) | KDM1AMAOBBTKDRD2DRD3 | |
| SCHEMBL622419 | 0.83 | BTK (0.51) | KDM1AMAOBBTKDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932261-B2 | Macrocycle derivatives useful as inhibitors of β-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-26 | — | — | US | disclosed |
| US-20070232630-A1 | MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232630-A1 | MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | KDM1A 4335/4885MAOB 948/4885BTK 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.